[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/MONDO_0024612",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/MONDO_0024612"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/DRUGBANK:DB01267"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/publications" : [ {
      "@id" : "https://pubmed.ncbi.nlm.nih.gov/31096228"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://w3id.org/um/neurodkg/OffLabelIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/DRUGBANK:DB01267",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion",
    "http://www.w3.org/ns/prov#generatedAtTime" : [ {
      "@value" : "2021-08-24T15:53:47.29208"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-09-13T13:11:54.555+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-7641-6446"
    } ],
    "http://purl.org/nanopub/x/supersedes" : [ {
      "@id" : "http://purl.org/np/RA5i91jVBRKHpwDOPIiWGzt3c3Rs8wAqKRXxOYhegMxOI"
    } ],
    "http://www.w3.org/ns/prov#generatedAtTime" : [ {
      "@value" : "2021-08-24T15:53:47.29208"
    } ],
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-7641-6446"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RAcm8OurwUk15WOgBM9wySo-T3a5h6as4K8YR5MBrrxUc"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RA2vCBXZf-icEcVRGhulJXugTGxpsV5yVr9yqCI1bQh4A"
    }, {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    }, {
      "@id" : "http://purl.org/np/RAjpBMlw3owYhJUBo3DtsuDlXsNAJ8cnGeWAutDVjuAuI"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "S36lxqMhE/il6hZ0x3opIf+BSGkgmrLS42CchAvMGjt03GhGQT20XdwHEBLps4EIevPEFYR3JCJttJowJ3HtWv4hSQ5sLxtGzcLW+7AD86Mrp/G3xGClqtMyQmf0MU7glLc83g8n8nenTaQOX37aaSuUPH+I3cZQJ1cSqTfX5ss="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#pubinfo"
} ]